JPRN-jRCT2080220594未知1 期
An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumors
Abbott Japan Co., Ltd.0 个研究点开始时间: 2008年8月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1. Subjects aged from 20 to 75 years at date of consent.
- •2. Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist.
排除标准
- 未提供
研究者
相似试验
已完成
1 期
A phase 1 mass balance study of [14C]TAS-205 in healthy volunteersDuchenne Muscular DystrophyJPRN-jRCT2071210008asermoaddeli Ali6
撤回
不适用
A phase I, open-label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy terminatioNA (healthy volunteers)10010273NL-OMON40897ObsEva SA6
尚未招募
4 期
An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.Opioid-induced ConstipationOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12611000002987The Royal Children's Hospital6
已完成
不适用
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered with Encorafenib and Binimetinib in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid TumorsNL-OMON55423Array BioPharma Inc. (a wholly ownd subsidairy of Pfizer Inc.)10
进行中（未招募）
1 期
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864EUCTR2017-002985-28-BEMerck KGaA148